Aplagon is a private pharmaceutical company focused on addressing unmet patient needs associated with the prevention of vascular injury related thrombotic blood vessel occlusions and ischemic reperfusion injuries.
Aplagon is developing APACs, biological mimetics of heparin proteoglycan, as potent, first-in-class antithrombotic products. The initial target indications include the clinical management of vascular injury-related thrombotic occlusions and ischemic reperfusion injuries. APACs also carry a lower bleeding risk than typical systemically acting antithrombotics.
APACs have a number of important and unique properties that include dual antiplatelet (AP) and anticoagulant (AC) modes of action, as well as the ability to target and act locally at the vascular injury site. In addition, they also beneficially influence vascular smooth muscle cells.
Aplagon was established to translate proprietary scientific discoveries on APACs from bed to bedside. The Company is supported by an experienced management team and Board, an excellent scientific network, and backed by a strong syndicate of leading Finnish investors.
Aplagon is partnered with Cadila Pharmaceuticals for the clinical development and commercialization of its lead APAC product in India. Together the companies are pursuing selected indications where the current treatments are not optimal.